University of North Carolina Lineberger Comprehensive Cancer Center researchers will share their expertise and latest findings at the American Association for Cancer Research Annual Meeting 2019, which is expected to draw thousands of scientists, physicians, advocates and others to Atlanta March 29-April 3.
New findings will be presented revealing insights behind connection between obesity and cancer, possible new therapeutic strategies to fight uterine cancer, and more.
Here are some of the presentations that will be made by UNC Lineberger members and their colleagues:
SATURDAY, MAR. 30
Functional Follow-Up of Microbiome Associations for Cancer Epidemiology Studies
Room B304 – Georgia World CC
4:15 – 4:40 PM
Fiber and colon cancer: Can we move from association to causal pathway?
Scott Bultman, University of North Carolina at Chapel Hill
SUNDAY, MAR. 31
1 – 2:45 PM
Obesity and Cancer: When Systemic Metabolism Meets Cell Metabolism
Georgia Ballroom 1- Bldg C- GWCC
Chairperson: Stephen D. Hursting, University of North Carolina at Chapel Hill
SY28-04 Obesity-associated leptin signaling promotes chemotherapy resistance in triple-negative breast cancer: The role of tumor-initiating cell enrichment
Laura W. Bowers, Joseph Gung, Claire G. Lineberger, Stephen D. Hursting. Purdue University, West Lafayette, IN, University of North Carolina at Chapel Hill
1 – 5 PM
Lifestyle Factors and Cancer Risk
642 / 26 Increasing BMI is associated with tumor volume and uterine weight in endometrial cancer
Yingao Zhang, Nerlyne Desravines, Dominic T. Moore, Paola A. Gehrig, Leslie H. Clark, Victoria L. Bae-Jump. University of North Carolina at Chapel Hill
New Anticancer Agents
361 / 22 NT1195, a novel biguanide, exhibits superior uterine penetration and anti-tumorigenic efficacy as compared to metformin/phenformin in endometrial cancer
Katherine Tucker1, Allison Staley1, Yali Fan1, Xiaoling Zhao1, Yajie Yin1, Ziwei Fang1, Wenchuan Sun1, Kenneth Batchelor2, Nick Livingston2, Chunziao Zhou1, Victoria Bae-Jump1. 1 University of North Carolina at Chapel Hill; 2NovaTarg Therapeutics, Durham, NC
Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer
410 / 12 Quantification and downstream analysis of circulating tumor cells isolated using CapioCyteTM liquid biopsy
Michael J. Poellmann1, Jiyoon Bu2, Dominic Moon3, Kyle Wagner3, Andrew Z. Wang3, Seungpyo Hong1. 1Univ. of Wisconsin Madison, Madison, WI; 2University of Wisconsin Madison, Madison, WI; 3University of North Carolina at Chapel Hill
Metabolic Mechanisms That Modulate the Immune Response to Cancer
503 / 2 Prostaglandin E2 produced by tumor cells or by the host tumor microenvironment is not completely abolished by aspirin or celecoxib and limits the ability of the host immune system to control tumor growth
John N. Snouwaert1, Leigh Jania1, MyTrang Nguyen1, Pragnya Dontu1, Jérôme Besse2, Barbara Akla2, Pierre J. Ferré2, Beverly H. Koller1. 1University of North Carolina at Chapel Hill; 2Inst. de Recherche Pierre Fabre, Toulouse Cedex 01, France
3 – 5 PM
Emerging Targets in Cancer Epigenetics
Room A302 – Georgia World CC
Chairperson: Scott Bultman. University of North Carolina, Chapel Hill, NC
Nutrition, Physical Activity, and Cancer Prevention: Current Status and Emerging Strategies
Room B401 – Georgia World CC
Chairperson: Stephen D. Hursting. University of North Carolina at Chapel Hill
5 – 7 PM
Personalized Career Conversations: Pathways to Academia, Industry, and Government
International Ballroom N – Hyatt
Presentation Mentor: Channing J. Der. UNC Lineberger Comp. Cancer Ctr., Chapel Hill, NC
6:30 – 8 PM
Networking Hubs
International Ballroom, Omni Hotel
Presentation: Stephen D. Hursting – Metabolism
MONDAY, APR. 1
8 AM – 12 PM
Laboratory and Computational Methods for Cancer Analysis
1678 / 29 Accurate detection of expressed variation in RNA-seq
Lisle E. Mose, David Marron, Joel S. Parker. UNC – Lineberger Cancer Center, Chapel Hill, NC
Tyrosine Kinase and Phosphatase Inhibitors 1
1314 / 3 MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia
Ryan J. Summers1, Katherine A. Minson1, Eleana Vasileiadi2, Xiaodong Wang3, Steven V. Frye3, H. Shelton Earp, III3, Deborah DeRyckere1, Douglas K. Graham1. 1Emory University, Atlanta, GA; 2Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta/Emory University, Atlanta, GA; 3University of North Carolina at Chapel Hill
Tumor-immune Interactions
1184 / 11 Comprehensive analysis with interactive exploration of immune response signatures in 10,000 tumor samples
Vesteinn Thorsson1, David L. Gibbs1, Mary L. Disis2, Elizabeth G. Demicco3, Alexander J. Lazar4, Jonathan S. Serody5, James A. Eddy6, Ilya Shmulevich1, Justin Guinney6, Benjamin G. Vincent5. 1Institute for Systems Biology, Seattle, WA; 2University of Washington, Seattle, WA; 3Mount Sinai Hospital, Toronto, ON, Canada; 4The University of Texas MD Anderson Cancer Center, Houston, TX; 5University of North Carolina at Chapel Hill; 6Sage Bionetworks, Seattle, WA
Cellular Responses to Anticancer Agents 1: The Microenvironment and Metastasis
1235 / 13 Targeting RNA-binding protein HuR to inhibit human breast cancer invasion and metastasis
Xiaoqing Wu1, Gulhumay Gardashova1, Lan Lan1, Shuang Han1, Cuncong Zhong1, Ragul Gowthaman1, John Karanicolas2, Dan A. Dixon1, Danny R. Welch3, Ling Li4, Min Ji5, Jeffrey Aubé6, Liang Xu1. 1Univ. of Kansas, Lawrence, KS; 2Fox Chase Cancer Center, Philadelphia, PA; 3Univ. of Kansas Medical Center, Kansas City, KS; 4The Air Force Medical University, Xi’an, China; 5Southeast University, Nanjing, China; 6University of North Carolina at Chapel Hill
Immune Cells in the Tumor Microenvironment
1090 / 13 β-Hydroxy-β-Methylbutyrate supplementation preserves muscle mass and reduces tumor growth in obese mice
Michael F. Coleman1, Kristyn A. Liu2, Xiaohu Tang3, Salvador Fabela1, Laura M. Lashinger2, Zhengrong Cui2, Stephen D. Hursting1. 1University of North Carolina at Chapel Hill; 2University of Texas, Austin, TX; 3Michigan Tech University, Houghton, MI Display Abstract
10:30 AM – 12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Marcus Auditorium- Bldg A-GWCC
10:33 – 10:56 AM
CT072 Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
Ryan J. Sullivan1, Stergios J. Moschos2, Melissa L. Johnson3, Mateusz Opyrchal4, Peter Ordentlich5, Susan Brouwer5, Serap Sankoh5, Michael L. Meyers6, Sanjiv S. Agarwala7. 1Massachusetts General Hospital, Boston, MA; 2University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; 3Sarah Cannon Research Institute, Nashville, TN; 4Roswell Park Comprehensive Cancer Center, Buffalo, NY; 5Syndax Pharmaceuticals, Inc., Waltham, MA; 6Syndax Pharmaceuticals, Inc., New York, NY; 7St. Luke’s Hospital, Easton, PA
10:30 AM – 12:15 PM
Cancer Detection with Proximate Biologic Specimens
Room A311 – Georgia World CC
11:30 AM – 11:55 AM
Lessons from studying molecular markers in stool for CRC screening
David F. Ransohoff. University of North Carolina at Chapel Hill
1 – 5 PM
Novel Imaging Techniques
1935 / 3 Tracking angiogenesis induced microvascular changes in a lymphoma model via a new high throughput non-invasive dual modality imaging platform
Juan D. Rojas1, Rajalekha Rajamahendiran1, Tomasz J. Czernuszewicz1, Brian Velasco2, Jonathan Perdomo1, Max Harlacher1, Graeme O’Connell1, James Butler1, Blossom Damania3, Paul A. Dayton2, Ryan C. Gessner1. 1SonoVol, Inc., Durham, NC; 2The University of North Carolina and North Carolina State University, Chapel Hill, NC; 3The University of North Carolina School of Medicine, Chapel Hill, NC
Novel Therapeutics and Pathways
2192A / 15 Combined MERTK and ROCK1/2 inhibition as a potential therapeutic strategy for AML
Dawn E. Barnes1, Xiaodong Wang2, Stephen V. Frye2, H. Shelton Earp, III3, Deborah DeRyckere1, Douglas K. Graham1. 1Emory University and Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA; 2Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; 3University of North Carolina at Chapel Hill
TUESDAY, APR. 2
8 AM – 12 PM
Factors Influencing Cancer Outcomes
3294 / 14 Urinary estrogen metabolites and long-term all-cause and cause-specific mortality following breast cancer diagnosis: A population-based study
Tengteng Wang1, Patrick B. Bradshaw2, Sarah J. Nyante1, Hazel B. Nichols1, Patricia G. Moorman3, Geoffrey C. Kabat4, Susan L. Teitelbaum5, Alfred I. Neugut6, Marilie D. Gammon1. 1University of North Carolina at Chapel Hill ; 2University of California, Berkeley, CA; 3Duke University, Durham, NC; 416 Bon Air Ave., New Rochelle, NY; 5Icahn School of Medicine at Mount Sinai, New York; 6Columbia University, New York
Immune Checkpoints 1
3223 / 3 Overcome LKB1 mutated cancer resistance to anti-PD1 treatment
Jiehui Deng1, Aatish Thennavan2, Yuanwang Pan1, Igor Dolgalev1, Ting Chen1, Heather Silver1, Matthew Harris1, Val Pyon1, Fei Li1, Chelsea Lee1, Aristotelis Tsirigos1, Eli Rothenberg1, Charles M. Perou2, Kwok-Kin Wong1. 1NYU Langone Medical Center, New York, NY; 2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Inflammation and Microbiome
Shannon B. McDonell1, Alyssa J. Cozzo1, Lydia K. Eisenbeis1, Andrew J. Dannenberg2, Stephen D. Hursting1. 1University of North Carolina at Chapel Hill; 2Weill Cornell Medical College, New York, NY
Laura A. Smith, Magdalena A. Rainey, Nishita T. Sheth, Stephanie A. Montgomery, Stephen D. Hursting. University of North Carolina at Chapel Hill
1- 5 PM
Applications of Cancer Computational Biology 2
4254 / 23 Integrated analysis with MVisAGe identifies concordant and discordant genomic alterations of driver genes
Vonn Walter1, Ying Du2, Ludmila Danilova3, Michele Hayward4, D. Neil Hayes5. 1Penn State College of Medicine, Hummelstown, PA; 2Center for Infection Disease Research, Seattle, WA; 3Johns Hopkins University School of Medicine, Baltimore, MD; 4University of North Carolina at Chapel Hill; 5University of Tennessee Health Science Center, Memphis, TN
Biomarkers and Immune Monitoring
4044 / 7 The immune phenotype in serial biopsies from metastatic TNBC undergoing chemo-immunotherapy
Jiehui Deng1, Suhagi Shah1, Aatish Thennavan2, Michelle Krogsgaard1, Charles M. Perou2, Kwok-Kin Wong1, Sylvia Adams1. 1NYU Langone Medical Center, New York, NY; 2Lineberger Comprehensive Cancer Center,University of North Carolina at Chapel Hill
Clinical Prevention, Early Detection, and Interception 2
4214 / 4 A microfluidic platform to capture and detect cancer cells in Leukemia patients
Rolf Muller1, Rachel Toughiri1, Alena Bartakova1, Paul Diaz1, Craig Carson1, Paul Armistead2, George Fedoriw2, Mathew Foster2, Maryam Zomorrodi1, Jennifer Barber-Singh1, Veronica Cheung1, Emily Mirkin2, Roksolana Melnychuk1, Elizabeth Fabio1, Sangeetha Purushotham1, Judy Muller-Cohn1. 1BioFluidica, San Diego, CA; 2University of North Carolina at Chapel Hill
4215 / 5 Patient and screening characteristics associated with positive lung cancer screening examinations
Louise M. Henderson1, Samantha Sites1, Tina Tailor2, Sara C. Bearden1, Roger Huamani1, Allison Throneburg1, Max Nagle1, M Patricia Rivera1. 1UNC Chapel Hill, Chapel Hill, NC; 2Duke University, Durham, NC
3 – 5 PM
Deregulated Transcription and RNA Processing in Cancer
Room A302 – Georgia World CC
4496 Cytokine-induced post-translational modifications of FOXA1 affect enhancer selection and estrogen signaling in breast cancer cells
Shen Li, Raul Mendez-Giraldez, Joseph P. Garay, Kamila Wisniewska, Colby A. Tubbs, Charles M. Perou, Hector L. Franco. Lineberger Comprehensive Cancer Center and the Department of Genetics at the University of North Carolina at Chapel Hill
WEDNESDAY, APR. 3
8 AM – 12 PM
Late-Breaking Research: Molecular and Cellular Biology / Genetics 2
LB-287 / 4 Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer
Craig M. Goodwin1, Sehrish Javaid1, Andrew M. Waters1, Bjoern Papke1, Runying Yang1, Mariaelena Pierobon2, Daniel M. Freed3, Patrick J. Roberts3, Adrienne D. Cox1, Kris C. Wood4, Emanuel F. Petricoin, III2, Autumn J. McRee5, Channing J. Der1. 1UNC Lineberger Comp. Cancer Ctr., Chapel Hill, NC; 2Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA; 3G1 Therapeutics, Research Triangle Park, NC; 4Department of Pharmacology and Cancer Biology, Duke University, Durham, NC; 5School of Medicine, University of North Carolina at Chapel Hill
Methods and Tools for Cancer Analysis
5094 / 2 SCOPE: A normalization and copy number estimation method for single-cell DNA sequencing
Rujin Wang, Danyu Lin, Yuchao Jiang. University of North Carolina at Chapel Hill
Late-Breaking Research: Experimental and Molecular Therapeutics 2
LB-276 / 22 Farnesyltransferase inhibitor (FTI)-induced growth inhibition of HRAS-mutant head and neck cancers is enhanced by concurrently inhibiting compensatory upregulation of the ERK-MAPK kinase cascade
Sehrish Javaid, Victoria V. Nguyen, Andrew M. Waters, Craig M. Goodwin, Channing J. Der, Adrienne D. Cox. University of North Carolina at Chapel Hill
10:20-10:45 a.m.
SY29-01 – The Cancer Tsunami: What is it and what does it mean for survivors, clinicians, and researchers?
Room B302 – Georgia World CC
Chairperson: Deborah K. Mayer, NCI and University of North Carolina at Chapel Hill